Funding News

Neuberg Diagnostics Is Going Public: $350M IPO Within 6 Months Could Be India's Biggest Diagnostics Listing Ever

By BHC, Editor in Chief · April 02, 2026 · 5 min read

BHC, Editor in Chief — Neuberg Diagnostics Is Going Public: $350M IPO Within 6 Months Could Be India's Biggest Diagnostics Listing Ever

Summary

  • Neuberg Diagnostics is preparing for a $350 million IPO within six months. Here is a complete breakdown of the company, the diagnostics market opportunity, and what the listing means for India's healthcare sector.

India's diagnostics sector is about to get its most significant IPO in years. Neuberg Diagnostics, one of the country's fastest-growing clinical laboratory and pathology chains, has confirmed that an initial public offering is on the cards within the next six months — targeting approximately $350 million, or roughly ₹3,200 crore, in what would be one of the largest primary issuances from India's diagnostics space to date.

The confirmation comes from senior management, with merchant bankers already appointed and regulatory filings expected imminently. The company has been building toward this moment systematically: it raised ₹940 crore from Kotak Alternate Asset Managers' Strategic Situations India Fund II in January 2025, capital earmarked specifically for inorganic growth and IPO readiness.

What Neuberg Is and What It Has Built

Founded in 2017 by Dr. GSK Velu, Neuberg Diagnostics has scaled at a pace that is remarkable even by the standards of India's fast-moving healthcare services sector. The company now operates more than 150 laboratories and 2,000+ patient collection centres across 250+ Indian cities. It is present internationally in the UAE, South Africa, Nepal, and has a genetic laboratory in the United States.

Neuberg's service portfolio spans the full spectrum of diagnostic medicine — from routine biochemistry and haematology to advanced genomics, haemato-oncology, histopathology, molecular diagnostics, and rare-disease panels. The company offers over 4,000 test categories, positioning itself as a multi-speciality provider rather than a commodity testing chain. This breadth in high-margin specialised testing is central to Neuberg's investment case.

The Numbers Behind the Story

Neuberg is targeting revenue of ₹20 billion for fiscal year 2027, up from an expected ₹16 billion for fiscal 2026 — a 25% growth trajectory. The company was valued at approximately $547 million as of December 2025, according to data from Tracxn. Its listed competitors give context: Metropolis Healthcare is valued at approximately ₹95 billion and Thyrocare at ₹57 billion. A successful IPO at the targeted size would represent a meaningful premium to Neuberg's last private valuation.

The Market Tailwind Is Real

India's diagnostics industry is projected to grow at 9.2% annually, reaching $26.7 billion by 2033. Some projections are more aggressive: Polaris Market Research and NATHEALTH suggest the broader Indian diagnostic market could reach $43.57 billion by fiscal 2032. The growth is driven by rising chronic disease prevalence, increasing preventive health awareness, expanding health insurance coverage, and growing demand for specialised testing in genomics, oncology, and infectious disease.

These tailwinds are not abstract. Every major Indian hospital network is expanding its diagnostic capacity. Government health schemes are driving higher testing volumes in tier-2 and tier-3 cities. And the shift toward preventive health — a megatrend accelerating globally — creates a structural demand for regular diagnostic screening that did not exist a decade ago.

What Comes After Neuberg

Dr. GSK Velu's healthcare portfolio extends well beyond Neuberg. He also owns Trivitron Healthcare, one of India's leading medical device manufacturers, and Maxivision Eye Hospitals, a growing ophthalmology chain. Management has confirmed that both companies are being evaluated for public listings following Neuberg's debut — suggesting a phased strategy to bring an entire healthcare portfolio to public markets over the next two to three years.

BHC Perspective

At Bengaluru Health Community, the Neuberg IPO is a landmark moment for the Indian healthcare capital markets story. Diagnostics has historically been an underfunded and undervalued segment in Indian healthcare investment — even though quality diagnostic infrastructure is foundational to everything else in the care continuum. A successful Neuberg listing at scale would validate the diagnostics sector as a serious institutional investment category, potentially unlocking capital for dozens of smaller regional diagnostic chains and health-tech companies building in the diagnostics space. We will be tracking every development in this IPO process closely.

Frequently Asked Questions

Q: When is Neuberg Diagnostics planning its IPO?
A: Neuberg Diagnostics has confirmed it is targeting an IPO within six months from early 2026 — meaning a listing by approximately September 2026, subject to regulatory clearances and market conditions.

Q: How much is Neuberg Diagnostics targeting to raise in its IPO?
A: The company is targeting approximately $350 million (around ₹3,200 crore) in what would be one of the largest IPOs from India's diagnostics sector.

Q: What does Neuberg Diagnostics do?
A: Neuberg is a multi-speciality diagnostics chain operating 150+ labs and 2,000+ collection centres across 250+ Indian cities and internationally. It offers 4,000+ tests ranging from routine bloodwork to genomics, haemato-oncology, and rare-disease diagnostics.